GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Prenetics Global Ltd (NAS:PRE) » Definitions » Net-Net Working Capital

Prenetics Global (Prenetics Global) Net-Net Working Capital

: $1.82 (As of Sep. 2023)
View and export this data going back to 2022. Start your Free Trial

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Prenetics Global's Net-Net Working Capital for the quarter that ended in Sep. 2023 was $1.82.

The industry rank for Prenetics Global's Net-Net Working Capital or its related term are showing as below:

PRE's Price-to-Net-Net-Working-Capital is ranked better than
78.1% of 105 companies
in the Medical Diagnostics & Research industry
Industry Median: 5.63 vs PRE: 1.92

Prenetics Global Net-Net Working Capital Historical Data

The historical data trend for Prenetics Global's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prenetics Global Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Net-Net Working Capital
- -1.87 -62.91 13.43

Prenetics Global Quarterly Data
Dec19 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Net-Net Working Capital Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.89 13.43 11.95 10.93 1.82

Competitive Comparison

For the Diagnostics & Research subindustry, Prenetics Global's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Prenetics Global Price-to-Net-Net-Working-Capital Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Prenetics Global's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Prenetics Global's Price-to-Net-Net-Working-Capital falls into.



Prenetics Global Net-Net Working Capital Calculation

Prenetics Global's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2022 is calculated as

Net-Net Working Capital(A: Dec. 2022 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(164.198+0.75 * 41.692+0.5 * 4.534-68.668
-0-6.399)/9.13221
=13.43

Prenetics Global's Net-Net Working Capital (NNWC) per share for the quarter that ended in Sep. 2023 is calculated as

Net-Net Working Capital(Q: Sep. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(68.845+0.75 * 4.477+0.5 * 3.29-47.63
-0-4.349)/12.0181
=1.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


Prenetics Global  (NAS:PRE) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


Prenetics Global Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Prenetics Global's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Prenetics Global (Prenetics Global) Business Description

Traded in Other Exchanges
N/A
Address
Unit 701-706, K11 Atelier King’s Road, 728 King’s Road, Quarry Bay, Hong Kong, HKG
Prenetics Global Ltd is a diagnostic and genetic testing company. It is a genomics and precision oncology company that has devised a method to integrate early detection for cancer, targeted therapy and direct-to-consumer genetic testing services into one comprehensive platform. It operates in two segments. The prevention segment includes the design & sale of genetics testing (including update services) & stool-based DNA tests for early colorectal cancer screening. The diagnostic segment includes the sale of COVID-19 testing services & products and precision oncology services. The majority of revenue is from the diagnostics segment. Geographically, it operates in Hong Kong and the United Kingdom, out of which the majority is from Hong Kong.